June 2026
M	T	W	T	F	S	S
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30

Pablo Corral on Why Early LDL-C Reduction Saves Lives

Pablo Corral/LinkedIn

Dec 7, 2025, 16:06

Pablo Corral on Why Early LDL-C Reduction Saves Lives

Pablo Corral, Pharmacology Professor at FASTA University, Past President of Argentine Lipid Society, shared on LinkedIn:

”Statins:

The Power of Early Intervention and the Reality of the Legacy Effect
The long arc of cardiovascular prevention continues to point in one direction: earlier LDL-C reduction delivers deeper, long-lasting protection. Two landmark analyses reinforce this principle with remarkable clarity.

The Scandinavian Simvastatin Survival Study (4S)—now revisited three decades after its publication—established that intensive LDL-C lowering not only reduces cardiovascular events but fundamentally alters long-term disease trajectories.

Its impact initiated a paradigm shift in dyslipidaemia management that persists today. (10.1016/S0140-6736(24)02089-0)

The ASCOT-Legacy 20-year follow-up extends this insight even further.

Despite convergence of lipid levels after trial completion, participants originally randomised to atorvastatin maintained significant long-term reductions in non-fatal myocardial infarction, fatal coronary heart disease, total coronary events, and cardiovascular mortality—demonstrating a true “legacy effect.”

Each 1 mmol/L lower in-trial LDL-C was associated with substantial long-term reductions in cardiovascular and all-cause mortality. (10.1136/heartjnl-2024-325104)

Key message:

Statins do more than lower LDL-C today—they reduce the cumulative cholesterol burden that determines tomorrow’s risk.
Starting earlier, treating consistently, and achieving lower LDL-C levels is not aggressive medicine—it is simply good medicine.

As the evidence mounts, the clinical imperative becomes harder to ignore:

Delay is costly.

Early, sustained lipid-lowering therapy saves lives.”

Pablo Corral on Why Early LDL-C Reduction Saves Lives